Despite recent treatment advances, estrogen receptor-positive (ER+) and HER2-negative (HER2−) advanced breast cancer (aBC) remains a heterogeneous disease with significant unmet need, particularly in patients relapsing early on treatment or shortly after completing adjuvant ET + CDK4/6i. This evidence concerns the gene CDK4 and aneurysmal bone cyst.